Login / Signup

Cutaneous toxicities of mitogen-activated protein kinase inhibitors in children and young adults with neurofibromatosis-1.

Brianna C PeacockSanjna TripathyHannah L HananiaHannah Y WangZsila S SadighiAnisha B Patel
Published in: Journal of neuro-oncology (2024)
Improvement in characterization of MEKi toxicities and their management is important to develop treatment guidelines for pediatric and young adult patients with NF1 on MEKi therapy.
Keyphrases
  • young adults
  • signaling pathway
  • childhood cancer
  • lps induced
  • oxidative stress
  • clinical practice
  • stem cells
  • immune response
  • inflammatory response
  • replacement therapy